HC Wainwright Lowers Earnings Estimates for Pharvaris

Pharvaris N.V. (NASDAQ:PHVS) – Research analysts at HC Wainwright dropped their FY2029 earnings per share (EPS) estimates for Pharvaris in a research report issued on Tuesday, October 6th. HC Wainwright analyst P. Trucchio now forecasts that the company will earn $2.88 per share for the year, down from their previous forecast of $3.09. HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($3.12) per share. HC Wainwright also issued estimates for Pharvaris’ FY2030 earnings at $6.62 EPS.

A number of other research firms have also commented on PHVS. HSBC upgraded shares of Pharvaris to an “overweight” rating in a research report on Thursday, August 13th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $65.00 price objective on shares of Pharvaris in a research report on Monday, September 14th. Royal Bank Of Canada lifted their price objective on Pharvaris from $52.00 to $62.00 and gave the company an “outperform” rating in a research note on Wednesday, September 9th. Wall Street Zen cut Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Pharvaris in a research note on Friday, July 17th. Thirteen research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Pharvaris presently has a consensus rating of “Moderate Buy” and a consensus target price of $58.60.

Pharvaris Trading Up 1.8%

Pharvaris stock opened at $31.68 on Wednesday. Pharvaris has a 1-year low of $20.65 and a 1-year high of $43.25. The firm has a market capitalization of $2.07 billion, a PE ratio of -10.39 and a beta of -2.46. The firm’s 50 day simple moving average is $34.91 and its 200 day simple moving average is $32.29.

Pharvaris (NASDAQ:PHVS) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing analysts’ consensus estimates of ($0.75) by ($0.06).

Insider Transactions at Pharvaris

In related news, insider Anne Lesage sold 30,000 shares of the company’s stock in a transaction on Thursday, September 10th. The shares were sold at an average price of $38.30, for a total value of $1,149,000.00. Following the completion of the transaction, the insider directly owned 56,450 shares in the company, valued at approximately $2,162,035. The trade was a 34.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Elisabeth Bjork sold 52,500 shares of the stock in a transaction on Thursday, September 17th. The shares were sold at an average price of $37.89, for a total value of $1,989,225.00. Following the completion of the transaction, the director directly owned 15,167 shares in the company, valued at approximately $574,677.63. This represents a 77.59% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 513,102 shares of company stock worth $18,643,666. Company insiders own 11.84% of the company’s stock.

Hedge Funds Weigh In On Pharvaris

Institutional investors have recently modified their holdings of the company. Quantbot Technologies LP purchased a new position in shares of Pharvaris in the second quarter valued at about $41,000. CoreCap Advisors LLC purchased a new stake in shares of Pharvaris during the second quarter worth about $93,000. Amundi boosted its holdings in shares of Pharvaris by 12.0% during the first quarter. Amundi now owns 30,952 shares of the company’s stock worth $874,000 after purchasing an additional 3,312 shares during the period. Sofinnova Investments Inc. grew its stake in shares of Pharvaris by 0.7% in the fourth quarter. Sofinnova Investments Inc. now owns 745,169 shares of the company’s stock worth $20,678,000 after purchasing an additional 5,293 shares during the last quarter. Finally, Public Employees Retirement System of Ohio bought a new stake in shares of Pharvaris in the second quarter worth about $196,000.

Pharvaris Company Profile

Pharvaris N.V. (NASDAQ:PHVS) is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE) and other diseases associated with bradykinin-mediated swelling. HAE is a rare genetic disorder that can cause recurring, potentially life-threatening attacks affecting areas such as the skin, gastrointestinal tract and airways.

The company’s lead program is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist formerly known as PHA121.